Reported Saturday, Johnson & Johnson's TALVEY Plus DARZALEX FASPRO Delivers Up To 81% PFS And 89% OS At 24 Months In First Phase 3 Study To Show Superior PFS For GPRC5D Bispecific Combination In Multiple Myeloma
Reported Saturday, Johnson & Johnson's TALVEY Plus DARZALEX FASPRO Delivers Up To 81% PFS And 89% OS At 24 Months In First Phase 3 Study To Show Superior PFS For GPRC5D Bispecific Combination In Multiple Myeloma
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day